DOCSLIB.ORG

Antibiotics: Past, Present and Future

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antibiotics: Past, Present and Future Available online at www.sciencedirect.com ScienceDirect Antibiotics: past, present and future 1 2 2 Matthew I Hutchings , Andrew W Truman and Barrie Wilkinson The first antibiotic, salvarsan, was deployed in 1910. In just over valuable compounds has resulted in the rapid rise of 100 years antibiotics have drastically changed modern antimicrobial resistance (AMR) with some infections medicine and extended the average human lifespan by now effectively untreatable [2]. The dangers of a post- 23 years. The discovery of penicillin in 1928 started the golden antibiotic era has prompted policymakers to acknowledge age of natural product antibiotic discovery that peaked in the this threat to human health and promise additional grant mid-1950s. Since then, a gradual decline in antibiotic discovery funding, which is gradually driving a resurgence of inter- and development and the evolution of drug resistance in many est in antibiotic discovery and development [3]. The UK human pathogens has led to the current antimicrobial Government-commissioned O’Neill report predicted that resistance crisis. Here we give an overview of the history of without urgent action 10 million people a year will die antibiotic discovery, the major classes of antibiotics and where from drug resistant infections by 2050 [4]. One of the key they come from. We argue that the future of antibiotic discovery recommendations is to stimulate early stage drug discov- looks bright as new technologies such as genome mining and ery [4]. Given the relative lack of success in bringing editing are deployed to discover new natural products with effective synthetic antibiotics to the clinic [5], the best diverse bioactivities. We also report on the current state of hope for developing a new generation of anti-infective antibiotic development, with 45 drugs currently going through drugs is to discover new microbial natural products (NPs) the clinical trials pipeline, including several new classes with because these compounds are unrivalled in their chemical novel modes of action that are in phase 3 clinical trials. Overall, diversity and effectiveness as antibiotics [1]. Filamentous there are promising signs for antibiotic discovery, but changes actinomycetes make 64% of the known NP antibiotic in financial models are required to translate scientific advances classes with the remainder made by other bacteria and into clinically approved antibiotics. fungi (Figure 2 and Table 1). Here we give a brief overview of the history of NP antibiotics and our pro- Addresses spects for discovering, developing and safeguarding a new 1 School of Biological Sciences, University of East Anglia, Norwich generation of antibiotics. Research Park, Norwich, NR4 7TJ, UK 2 Department of Molecular Microbiology, John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK A brief history of antibiotics The use of antibiotic-producing microbes to prevent Corresponding authors: Hutchings, Matt ([email protected]), disease stretches back millennia, with traditional poul- Truman, Andrew ([email protected]), tices of mouldy bread being used to treat open wounds in Wilkinson, Barrie ([email protected]) Serbia, China, Greece and Egypt more than 2000 years ago. The Eber’s papyrus from 1550 BC is the oldest Current Opinion in Microbiology 2019, 51:72–80 preserved medical document and includes mouldy bread This review comes from a themed issue on Antimicrobials and medicinal soil amongst its list of remedies [6]. An Anglo-Saxon recipe from 1000 years ago was also recently Edited by Mattew I Hutchings, Andrew W Truman and Barrie Wilkinson shown to kill MRSA (methicillin-resistant Staphylococcus aureus) [7 ]. However, the development of anti-infective For a complete overview see the Issue and the Editorial drugs and the underlying concept of chemotherapy is Available online 13th November 2019 widely accredited to Paul Ehrlich, who developed the https://doi.org/10.1016/j.mib.2019.10.008 synthetic arsenic-based pro-drugs salvarsan (salvation ã 1369-5274/ 2020 The Authors. Published by Elsevier Ltd. This is an arsenic) and neo-salvarsan circa 100 years ago to treat open access article under the CC BY license (http://creativecommons. Treponema pallidum, the causative agent of syphilis [8] org/licenses/by/4.0/). (Figure 1). This represented one of the first systematic screens for drug discovery using a library of synthetic compounds and was inspired by Ehrlich’s work on dyes that specifically stained bacterial cells. Salvarsan was superseded by the sulfonamide prodrug Prontosil, discov- The development of antibiotics ered by Gerhard Domagk [9], a bacteriologist at Bayer The introduction of antibiotics into clinical use was who used the drug to save his daughter’s arm from arguably the greatest medical breakthrough of the 20th amputation. Domagk and colleagues were effectively century (Figure 1) [1]. In addition to treating infectious continuing the work of Paul Ehrlich because the sulfa diseases, antibiotics made many modern medical proce- drugs were inspired by dyes that were used to selectively dures possible, including cancer treatment, organ trans- stain bacterial cells. Sulfonamides were the first truly plants and open-heart surgery. However, misuse of these effective, broad spectrum antimicrobials in clinical use Current Opinion in Microbiology 2019, 51:72–80 www.sciencedirect.com Antibiotics: past, present and future Hutchings, Truman and Wilkinson 73 Figure 1 Macro lides KEY Glycopep tides Actino mycete natural products Tuberactinomycins Othe r bacterial natural products Polymyxins Fungal na tural products Nitrofurans Synthet ic antibiotics Pyridinamides Phosphonates *Ind icates that synthesis was inspir ed by a natural product Ansamycins Lin cosamides Aminoglycosides Strep togramins Tetracyclines Cyclo serine Amphenicols Fusidic acid Polypeptides Cephalo sporins Lipiarmycins Bacitracin Ennia tins Diarylquinolines Penicillins Quin olones Salvarsan is no Sulfones Azoles* Salicylates longer in clinical use Phenazines* Carbapenems Lip opeptides Diaminopyrimidines Mupirocin Ple uromutilins Salvarsan Sulfonamides Ethambutol Monobactams Oxazolidin ones Thioamide s 1900 1910 1920 19301940 19501960 19701980199020002010 Golden Last class of First synthetic Penicillin Penicillin Age clinically-used NP First actinomycete antibiotic used discovered approved for antibio tic discovered genome sequenced clinically clinical use MRSA first detected First report of VRSA first VRE first antibiosis by First systematic Streptomycin detected analysis of anti biosis actinomycetes discovered detected by soil bact eria Penicillin Plas mid borne Plasmid-borne colistin resistance resistan ce to resistance in Resistance to identified sulfona mides Enterobacteriaceae. salvarsan Resistance to UN declares AMR a sulfonamides “funda mental threat” Current Opinion in Microbiology Timeline showing the decade new classes of antibiotic reached the clinic. The antibiotics are coloured per their source: green = actinomycetes, blue = other bacteria, purple = fungi and orange = synthetic. At the bottom of the timeline are key dates relating to antibiotic discovery and antimicrobial resistance, including the first reports of drug resistant strains methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), vancomycin-resistant S. aureus (VRSA) and plasmid-borne colistin resistance in Enterobacteriaceae. and are still in use today, but they were largely super- who proposed that microbes could secrete material to kill seded by the discovery of penicillin, observed on a other bacteria [14]. The production of diffusible and heat- contaminated Petri dish by Alexander Fleming in stable compounds by bacteria was being reported by the th 1928 [10]. Penicillin was later purified by Norman Heat- turn of the 20 century [15], and their utility in com- ley, Howard Florey, Ernst Chain and colleagues at batting infectious diseases had been explored. Arguably Oxford, who were instrumental in the development of the first clinical use of an antibiotic was reported in the penicillin as a drug [11] (Figure 1). Dorothy Hodgkin 1890s, where Emmerich and Lo¨w used an extract of solved the beta-lactam structure of penicillin in 1945 [12]. Pseudomonas aeruginosa (then known as Bacillus pycyaneus) resolving the famous debate between Robert Robinson, to treat hundreds of patients and this extract, called who favoured a thiazolidine-oxazolone structure, and pyocyanase, was used until the 1910s [16]. Pyocyanase several other notable chemists including Chain, Abra- was active towards multiple pathogens and incorrectly hams and Woodward, who believed it to be a beta-lactam believed to be an enzyme. Instead, the active components [13]. This was an important breakthrough because it of pyocyanase was likely to be a mixture of pyocyanin, a enabled the development of semi-synthetic derivatives quorum sensing phenazine, and 2-alkyl-4-hydroxy-qui- to bypass penicillin resistance. nolones [17]. Antibiosis between microbes was described well before The discoveries of penicillin, tyrocidine and numerous the discovery of penicillin, including by Louis Pasteur, reports of the production of antimicrobial compounds by www.sciencedirect.com Current Opinion in Microbiology 2019, 51:72–80 74 Antimicrobials Figure 2 Actino mycetes Lincosam ides Chloramphenicol Lipoglyc opeptides Synthetic Carbapenems Other bacteria Fungal Lipopeptides Macrolides Azoles* Penicillins Ansamycins Fosfomyc in Mupirocin Nitrofurans Aminoglycosides Cephalospo rins Streptogramins Monobacta
Load more

Recommended publications
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • Infection Prevention in Combat-Related Injuries CPG ID: 24 APPENDIX B: POST-INJURY ANTIMICROBIAL AGENT SELECTION and DURATION BASED UPON INJURY PATTERN
    Infection Prevention in Combat-Related Injuries CPG ID: 24 APPENDIX B: POST-INJURY ANTIMICROBIAL AGENT SELECTION AND DURATION BASED UPON INJURY PATTERN INJURY PREFERRED AGENT(S) ALTERNATE AGENT(S) DURATION EXTREMITY WOUNDS (INCLUDES SKIN, SOFT TISSUE, BONE) Skin, soft tissue, no open fractures Cefazolin, 2 gm IV q6-8h†‡ Clindamycin (300-450 mg PO TID or 600 mg IV q8h) 1-3 days Skin, soft tissue, with open Cefazolin 2 gm IV q6-8h†‡§ Clindamycin 600 mg IV q8h 1-3 days fractures, exposed bone, or open joints THORACIC WOUNDS Penetrating chest injury without Cefazolin, 2 gm IV q6-8h†‡ Clindamycin (300-450 mg PO TID or 600 mg IV q8h) 1 day esophageal disruption Penetrating chest injury with Cefazolin 2 gm IVq 6-8h†‡ PLUS metronidazole 500 Ertapenem 1 gm IV x 1 dose, OR moxifloxacin 400 mg 1 day after definitive esophageal disruption mg IV q8-12h IV x 1 dose washout ABDOMINAL WOUNDS Penetrating abdominal injury with Cefazolin 2 gm IV q 6-8h†‡ PLUS metronidazole 500 Ertapenem 1 gm IV x 1 dose, OR moxifloxacin 400 mg 1 day after definitive suspected/known hollow viscus mg IV q8-12h IV x 1 dose washout injury and soilage; may apply to rectal/perineal injuries as well MAXILLOFACIAL AND NECK WOUNDS Open maxillofacial fractures, or Cefazolin 2 gm IV q6-8h†‡ Clindamycin 600 mg IV q8h 1 day maxillofacial fractures with foreign body or fixation device CENTRAL NERVOUS SYSTEM WOUNDS Penetrating brain injury Cefazolin 2 gm IV q6-8h.†‡ Consider adding Ceftriaxone 2 gm IV q24h. Consider adding 5 days or until CSF metronidazole 500 mg IV q8-12h if gross metronidazole 500 mg IV q8-12h if gross contamination with organic debris contamination with organic debris.
    [Show full text]
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2
    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
    [Show full text]
  • Multiplex De Novo Sequencing of Peptide Antibiotics
    JOURNAL OF COMPUTATIONAL BIOLOGY Volume 18, Number 11, 2011 Research Articles # Mary Ann Liebert, Inc. Pp. 1371–1381 DOI: 10.1089/cmb.2011.0158 Multiplex De Novo Sequencing of Peptide Antibiotics HOSEIN MOHIMANI,1 WEI-TING LIU,2 YU-LIANG YANG,3 SUSANA P. GAUDEˆ NCIO,4 WILLIAM FENICAL,4 PIETER C. DORRESTEIN,2,3 and PAVEL A. PEVZNER5 ABSTRACT Proliferation of drug-resistant diseases raises the challenge of searching for new, more efficient antibiotics. Currently, some of the most effective antibiotics (i.e., Vancomycin and Daptomycin) are cyclic peptides produced by non-ribosomal biosynthetic pathways. The isolation and sequencing of cyclic peptide antibiotics, unlike the same activity with linear peptides, is time-consuming and error-prone. The dominant technique for sequencing cyclic peptides is nuclear magnetic resonance (NMR)–based and requires large amounts (milli- grams) of purified materials that, for most compounds, are not possible to obtain. Given these facts, there is a need for new tools to sequence cyclic non-ribosomal peptides (NRPs) using picograms of material. Since nearly all cyclic NRPs are produced along with related analogs, we develop a mass spectrometry approach for sequencing all related peptides at once (in contrast to the existing approach that analyzes individual peptides). Our results suggest that instead of attempting to isolate and NMR-sequence the most abundant com- pound, one should acquire spectra of many related compounds and sequence all of them simultaneously using tandem mass spectrometry. We illustrate applications of this approach by sequencing new variants of cyclic peptide antibiotics from Bacillus brevis, as well as sequencing a previously unknown family of cyclic NRPs produced by marine bacteria.
    [Show full text]
  • Adenylation Enzyme Characterization Using Γ -18O4-ATP
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Chemistry & Biology Brief Communication Adenylation Enzyme Characterization 18 Using g - O4-ATP Pyrophosphate Exchange Vanessa V. Phelan,1 Yu Du,1 John A. McLean,1 and Brian O. Bachmann1,* 1Department of Chemistry, Vanderbilt University, Nashville, TN 37204, USA *Correspondence: [email protected] DOI 10.1016/j.chembiol.2009.04.007 SUMMARY ceuticals including penicillin, vancomycin, and rapamycin, to name a few (Fischbach and Walsh, 2006; Sieber and Marahiel, We present here a rapid, highly sensitive nonradioac- 2005). tive assay for adenylation enzyme selectivity determi- The biochemical assay of decoupled synthetases poses prac- nation and characterization. This method measures tical challenges because most adenylation reactions are not the isotopic back exchange of unlabeled pyrophos- formally catalytic. Isolated synthetases perform half-reactions 18 (Figure 1B) for subsequent amino acid (thio)esterification that phate into g- O4-labeled ATP via matrix-assisted laser desorption/ionization time-of-flight mass spec- are nearly stoichiometric with regard to their respective tRNA/T domains and aminoacyl adenylates are tightly bound enzyme trometry (MS), electrospray ionization liquid chroma- intermediates. Conventionally, adenylation enzyme selectivity tography MS, or electrospray ionization liquid chro- has been assayed using the ATP-32PPi (pyrophosphate) isotope matography-tandem MS and is demonstrated for exchange assay. In this method, the synthetase is incubated with both nonribosomal (TycA, ValA) and ribosomal excess 32PPi, amino acid, and ATP, and the reversible back synthetases (TrpRS, LysRS) of known specificity. exchange of labeled 32PPi into ATP is monitored by solid-phase This low-volume (6 ml) method detects as little as capture of ATP on activated charcoal followed by scintillation 0.01% (600 fmol) exchange, comparable in sensitivity counting.
    [Show full text]
  • Sulfonamides and Sulfonamide Combinations*
    Sulfonamides and Sulfonamide Combinations* Overview Due to low cost and relative efficacy against many common bacterial infections, sulfonamides and sulfonamide combinations with diaminopyrimidines are some of the most common antibacterial agents utilized in veterinary medicine. The sulfonamides are derived from sulfanilamide. These chemicals are structural analogues of ρ-aminobenzoic acid (PABA). All sulfonamides are characterized by the same chemical nucleus. Functional groups are added to the amino group or substitutions made on the amino group to facilitate varying chemical, physical and pharmacologic properties and antibacterial spectra. Most sulfonamides are too alkaline for routine parenteral use. Therefore the drug is most commonly administered orally except in life threatening systemic infections. However, sulfonamide preparations can be administered orally, intramuscularly, intravenously, intraperitoneally, intrauterally and topically. Sulfonamides are effective against Gram-positive and Gram-negative bacteria. Some protozoa, such as coccidians, Toxoplasma species and plasmodia, are generally sensitive. Chlamydia, Nocardia and Actinomyces species are also sensitive. Veterinary diseases commonly treated by sulfonamides are actinobacillosis, coccidioidosis, mastitis, metritis, colibacillosis, pododermatitis, polyarthritis, respiratory infections and toxo- plasmosis. Strains of rickettsiae, Pseudomonas, Klebsiella, Proteus, Clostridium and Leptospira species are often highly resistant. Sulfonamides are bacteriostatic antimicrobials
    [Show full text]
  • E3 Appendix 1 (Part 1 of 2): Search Strategy Used in MEDLINE
    This single copy is for your personal, non-commercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, contact CJHP at [email protected] Appendix 1 (part 1 of 2): Search strategy used in MEDLINE # Searches 1 exp *anti-bacterial agents/ or (antimicrobial* or antibacterial* or antibiotic* or antiinfective* or anti-microbial* or anti-bacterial* or anti-biotic* or anti- infective* or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or clindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).kf,kw,ti. or (antimicrobial or antibacterial or antiinfective or anti-microbial or anti-bacterial or anti-infective or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or c lindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).ab. /freq=2 2 alamethicin/ or amdinocillin/ or amdinocillin pivoxil/ or amikacin/ or amoxicillin/ or amphotericin b/ or ampicillin/ or anisomycin/ or antimycin a/ or aurodox/ or azithromycin/ or azlocillin/ or aztreonam/ or bacitracin/ or bacteriocins/ or bambermycins/ or bongkrekic acid/ or brefeldin a/ or butirosin sulfate/ or calcimycin/ or candicidin/ or capreomycin/ or carbenicillin/ or carfecillin/ or cefaclor/ or cefadroxil/ or cefamandole/ or cefatrizine/ or cefazolin/ or cefixime/ or cefmenoxime/ or cefmetazole/ or cefonicid/ or cefoperazone/
    [Show full text]
  • 1.Why Are Sulfonamide Antibacterials Acidic?
    STUDY GUIDE 2: SYNTHETIC ANTIBACTERIALS: THE SULFONAMIDES: 1.Why are sulfonamide antibacterials acidic? Why are sulfonamides such as sulfisoxazole more acidic than sulfacetamide or sulfanilamide? Understand the relationship between resonance and acidity and be able to apply it relative acidity. 2. Why does the water solubility of the sulfonamides decrease as pH decreases as indicated in Table 1? DON'T MEMORIZE this table, just understand it. 3. What factors determine water solubility/lipophilicity 4. Do not memorize the drug structures shown in the chapter. You will not be asked to recall these from memory (see 24 below). 5. What bacterial enzyme does the sulfonamides inhibit to produce its chemotherapeutic effect? Why are they capable of inhibiting this enzyme? Specifically, how does this result in decreased bacterial DNA synthesis? Is this a static or cidal action? 6. What role does ionization and pKa play in mechanism of action and entry in target bacteria? 8. YOU NEED NOT MEMORIZE the folate biosynthetic scheme, but if given the structures of PABA and the DPAD precursor, you should be able to draw the structure of the DIHYDRO- PTEROATE product. 7. Why are the sulfonamides selectively toxic to bacterial cells versus mammalian cells (Selectivity)? 8. How and why do sulfonamides function as pseudo-substrates? 9. What are the known mechanisms of resistance to the sulfonamides? What is the MAJOR mechanism and how is it transferred to other bacteria? Which other antibacterial drug are sulfon- amide-resistant bacteria resistant to and why? 10. What gram positive and gram negative bacteria are the sulfonamides effective against. DON'T MEMORIZE TABLE 2.
    [Show full text]
  • Structural Basis for the Activation of Phenylalanine in the Non-Ribosomal Biosynthesis of Gramicidin S
    The EMBO Journal Vol.16 No.14 pp.4174–4183, 1997 Structural basis for the activation of phenylalanine in the non-ribosomal biosynthesis of gramicidin S Elena Conti1,2, Torsten Stachelhaus3, the peptide product. Each amino acid is activated by Mohamed A.Marahiel3 and Peter Brick1,4 adenylation of its carboxylate group with ATP and then transferred to the thiol group of an enzyme-bound phospho- 1Biophysics Section, Blackett Laboratory, Imperial College, pantetheine cofactor for possible modification and the 3 London SW7 2BZ, UK and Biochemie/Fachbereich Chemie, elongation reaction (Stachelhaus and Marahiel, 1995a; Philipps-Universita¨t Marburg, D-35032 Marburg, Germany Kleinkauf and von Do¨hren, 1996). 2 Present address: Laboratory of Molecular Biophysics, The cloning and sequencing of several peptide synthe- Rockefeller University, New York, NY10021, USA tase genes have revealed a conserved and ordered modular 4Corresponding author organization. Each module encodes a functional building unit containing ~1000 amino acids, which specifically The non-ribosomal synthesis of the cyclic peptide recognizes a single amino acid. Within such a protein antibiotic gramicidin S is accomplished by two large template-directed peptide biosynthesis, the occurrence and multifunctional enzymes, the peptide synthetases 1 and specific order of the modules in the genomic DNA dictate 2. The enzyme complex contains five conserved subunits the number and sequence of the amino acids to be of ~60 kDa which carry out ATP-dependent activation incorporated into the resulting oligopeptide. The modular of specific amino acids and share extensive regions of arrangement of peptide synthetases closely parallels the sequence similarity with adenylating enzymes such multienzyme complexes responsible for the biogenesis of as firefly luciferases and acyl-CoA ligases.
    [Show full text]
  • | Hao Wanathi Movie Plena Matuma Wa Mt
    |HAO WANATHI MOVIEUS009943500B2 PLENA MATUMA WA MT (12 ) United States Patent ( 10 ) Patent No. : US 9 ,943 , 500 B2 Page (45 ) Date of Patent: Apr . 17 , 2018 ( 54 ) METHODS OF TREATING TOPICAL A61K 9 /0046 ; A61K 9 / 06 ; A61K 47 /10 ; MICROBIAL INFECTIONS A61K 47 / 14 ; A61K 47 / 44 ; A61K 9 /0048 ; A61K 47/ 06 ; A61L 15 / 46 ; A61L ( 71 ) Applicant: LUODA PHARMA PTY LIMITED , 2300 /404 ; A61L 26 /0066 Caringbah ( AU ) See application file for complete search history . (72 ) Inventor : Stephen Page , Newtown ( AU ) ( 56 ) References Cited (73 ) Assignee : Luoda Pharma Pty Ltd , Caringbah U . S . PATENT DOCUMENTS (AU ) 3 ,873 , 693 A 3 / 1975 Meyers et al . 3 , 920 ,847 A * 11/ 1975 Chalaust .. .. A61K 9 /0014 Subject to any disclaimer, the term of this 514 / 512 ( * ) Notice : 4 ,772 , 470 A * 9 / 1988 Inoue .. .. .. .. .. A61K 9 / 006 patent is extended or adjusted under 35 424 / 435 U . S . C . 154 ( b ) by 0 days . 2005/ 0187199 Al * 8 /2005 Peyman .. .. .. A61K 8 / 36 514 / 154 ( 21) Appl. No .: 14 / 766 , 232 FOREIGN PATENT DOCUMENTS ( 22 ) PCT Filed : FebD . 10 , 2014 EP 0294538 A2 12 / 1988 WO WO - 2003/ 088965 A1 10 / 2003 ( 86 ) PCT No . : PCT/ AU2014 /000101 WO WO - 2006 /081327 A2 8 /2006 $ 371 ( c ) ( 1 ) , WO WO - 2008 /075207 A2 6 / 2008 ( 2 ) Date : Aug. 6 , 2015 OTHER PUBLICATIONS (87 ) PCT Pub . No .: W02014 / 121342 Weese et. al. , Veterinary Microbiology , 2010 , Elsevier, vol. 140 , pp . PCT Pub . Date : Aug . 14 , 2014 418 - 429 . * Brindle , Encyclopedia of Chemical Technology . Polyether antibi otics, Nov . 2013 , Wiley , Abstract and pp .
    [Show full text]
  • By Nicole M. Gaudelli
    MECHANISTIC AND STRUCTURAL STUDIES OF THE THIOESTERASE DOMAIN IN THE TERMINATION MODULE OF THE NOCARDICIN NRPS By Nicole M. Gaudelli A dissertation submitted to The Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, MD 2013 © Nicole M. Gaudelli 2013 All Rights Reserved Abstract The nocardicins are monocyclic -lactam antibiotics produced by the actinomycete Nocardia uniformis subsp., tsuyamanensis ATCC 21806. In 2004 the gene cluster responsible for the biosynthesis of the flagship antibiotic, nocardicin A, was identified. This gene cluster accommodates a pair of non- ribosomal peptide synthetase (NRPS) whose five modules are indispensible for antibiotic production. In accordance with the prevailing co-linearity model of NRPS function, a linear L,L,D,L,L pentapeptide was predicted to be synthesized. Contrary to expectation and precedent, however, a stereodefined series of synthesized potential peptide substrates for the nocardicin thioesterase (NocTE) domain failed to undergo hydrolysis. The stringent discrimination against peptide intermediates was dramatically overcome by prior monocyclic -lactam formation at an L-seryl site to render now facile substrates for C-terminal epimerization and hydrolytic release. It was concluded through biochemical and kinetic experimentation that the TE domain acts as a gatekeeper to hold the assembling peptide on an upstream domain until -lactam formation takes place and then rapidly catalyzes epimerization and hydrolysis to discharge a fully-fledged pentapeptide -lactam harboring nocardicin G, the simplest member of the nocardicin family. An x-ray crystal structure of the TE domain revealed a catalytic center containing the expected Asp, His, Ser triad. Mutational analysis of these catalytic residues along with a proximal His established that the His of the catalytic triad was likely responsible for the epimerization activity rendered by the domain.
    [Show full text]
  • Syntheses and Structural Studies of Metal Complexes of Sulfa Drugs
    SYNTHESES AND STRUCTURAL STUDIES OF METAL COMPLEXES OF SULFA DRUGS A thesis submitted to the Cardiff University By G. M. Golzar Hossain in candidature of the degree of Doctor of Philosophy August 2005 Department of Chemistry Cardiff University UMI Number: U584873 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. Dissertation Publishing UMI U584873 Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author. Microform Edition © ProQuest LLC. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 DECLARATION This work has not previously been accepted in substance for any degree and is not being concurrently submitted in candidature for any degree. Signed (Candidate) Date: O 3 / ^ 6 STATEMENT 1 This thesis is the result of my own investigations, except where otherwise stated. Other sources are acknowledged by in the appended bibliography. Signed (Candidate) Date: STATEMENT 2 I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter-library loan, and for the title and summary to be made available to outside organisations. Signed (Candidate) Date: / 3 / o 3 / II <tm ^d ic a te < d t o JAfroza andJAsif III ACKNOWLEDGEMENTS This work would not have been completed without the encouragement and patience of my supervisors Professor Peter G.
    [Show full text]